With positive Phase 2 study results and ongoing pivotal trials, Pharvaris is positioned to deliver significant topline data by 2026, which could act as a value inflection point. Furthermore, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback